BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28508247)

  • 21. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
    Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
    Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts.
    Heim C; Eckl S; Preidl R; Ramsperger-Gleixner M; Koch N; Goldmann K; Spriewald BM; Weyand M; Ensminger SM
    Eur J Cardiothorac Surg; 2015 Jan; 47(1):180-7. PubMed ID: 24674907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
    Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
    Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.
    Levitsky J; Miller J; Huang X; Gallon L; Leventhal JR; Mathew JM
    PLoS One; 2016; 11(6):e0156535. PubMed ID: 27275747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus.
    Poncelet AJ; Nizet Y; Vercruysse J; Hiel AL; Saliez A; Gianello P
    Transplantation; 2008 Dec; 86(11):1586-95. PubMed ID: 19077894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus.
    Demmers MW; Baan CC; Janssen M; Litjens NH; Ijzermans JN; Betjes MG; Weimar W; Rowshani AT
    Transplantation; 2014 Jan; 97(1):47-55. PubMed ID: 24157471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
    Reinders ME; Bank JR; Dreyer GJ; Roelofs H; Heidt S; Roelen DL; Al Huurman V; Lindeman J; van Kooten C; Claas FH; Fibbe WE; Rabelink TJ; de Fijter JW
    J Transl Med; 2014 Dec; 12():331. PubMed ID: 25491391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
    Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
    Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thirty Years of Tacrolimus in Clinical Practice.
    Ong SC; Gaston RS
    Transplantation; 2021 Mar; 105(3):484-495. PubMed ID: 32541562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction.
    Takahashi HK; Iwagaki H; Yagi T; Kanke T; Liu K; Yoshino T; Tanaka N; Nishibori M
    Clin Immunol; 2007 Jun; 123(3):324-32. PubMed ID: 17482516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.
    van Rossum HH; Romijn FP; Smit NP; de Fijter JW; van Pelt J
    Biochem Pharmacol; 2009 Apr; 77(7):1206-12. PubMed ID: 19154728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
    Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
    Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
    Lemaitre F; Antignac M; Fernandez C
    Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
    Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
    Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
    Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
    Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
    Bocian K; Borysowski J; Wierzbicki P; Wyzgal J; Klosowska D; Bialoszewska A; Paczek L; Górski A; Korczak-Kowalska G
    Nephrol Dial Transplant; 2010 Mar; 25(3):710-7. PubMed ID: 19903662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.